Similarly, in previous studies, positive BCL2 expression has been associated with an increased risk of recurrence, poor treatment response, and shorter PFS and OS in lymphoma patients [83,84,85,86], as well as poor therapy response in acute leukemia [87]. This evidence concerns the gene BCL2 and lymphoma.